As health systems seek to balance innovation with the need to address sustainability, increasing attention is being paid to ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five ...

A Somerset woman says she suffered a severe asthma attack after having her prescription changed without consultation. Sue* has lived with asthma for 42 years and is used to using a blue inhaler. But ...

Pulmonary arterial hypertension (PAH) is a severe disease responsible for high mortality in the affected population. Due to the limitations in treatment as severe adverse effects, high cost, we aimed ...

Key market opportunities in the inhaler solution market include the rising demand driven by increased respiratory disorders like asthma and COPD, expanding access to medicines in low and middle-income ...

Move comes 2 years after controversial exit of brand-name product ...

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide. The FDA has authorized the first generic version of fluticasone ...

Add Yahoo as a preferred source to see more of our stories on Google. Children who use a lot of blue reliever inhalers are several times more likely to have severe asthma attacks [BBC] A new study is ...